Stay updated with breaking news from வாலிட் அபீ ஸாப். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF FOSTER CITY, Calif. & MECHELEN, Belgium (BUSINESS WIRE) Galapagos NV (Euronext & Nasdaq: GLPG) and Gilead Sciences (Nasdaq: GILD) today announced the decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor ziritaxestat in patients with idiopathic pulmonary fibrosis. The decision is based on the recommendations of the Independent Data Monitoring Committee (IDMC) which, following a regular review of unblinded data, concluded that ziritaxestat’s benefit-risk profile no longer supported continuing these studies. Detailed data of the ISABELA studies will be presented at future medical meetings. Investigators are being informed of the decision and they will be contacting their study participants to discontinue the investigational treatment. ....